drug
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
Marketedupdated 3mo agoby Apotex Corp
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugNORGESTIMATE AND ETHINYL ESTRADIOL87 co-mentions · 18 sources
- drugDAYSEE78 co-mentions · 18 sources
- drugESTRING76 co-mentions · 18 sources
- tagApproval74 co-mentions · 16 sources
- tagSmall Molecule37 co-mentions · 16 sources
- drugnorethindrone24 co-mentions · 8 sources
- companyGlenmark Pharmaceuticals Ltd6 co-mentions · 1 sources
- drugDESOGESTREL AND ETHINYL ESTRADIOL4 co-mentions · 2 sources
all catalysts(15)
approval · 15
Apr 10, 2013
approval
DAYSEE (ETHINYL ESTRADIOL) — FDA approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
→
Jan 27, 2016
approval
NORGESTIMATE AND ETHINYL ESTRADIOL (ETHINYL ESTRADIOL) — FDA approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
→
Dec 26, 2017
approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (ETHINYL ESTRADIOL) — FDA approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
→
Mar 21, 2018
approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (ETHINYL ESTRADIOL) — FDA approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
→
May 29, 2018
approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (ETHINYL ESTRADIOL) — FDA approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
→
Nov 9, 2018
approval
NORGESTIMATE AND ETHINYL ESTRADIOL (ETHINYL ESTRADIOL) — FDA approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
→
Nov 9, 2018
approval
NORGESTIMATE AND ETHINYL ESTRADIOL (ETHINYL ESTRADIOL) — FDA approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
→
Apr 29, 2022
approval
NORGESTIMATE AND ETHINYL ESTRADIOL (ETHINYL ESTRADIOL) — FDA approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
→
Apr 29, 2022
approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (ETHINYL ESTRADIOL) — FDA approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
→
Oct 1, 2025
approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (ETHINYL ESTRADIOL) — FDA approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
→
Oct 1, 2025
approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (ETHINYL ESTRADIOL) — FDA approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
→
Oct 1, 2025
approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (ETHINYL ESTRADIOL) — FDA approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
→
Jan 7, 2026
approval
NORGESTIMATE AND ETHINYL ESTRADIOL (ETHINYL ESTRADIOL) — FDA approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
→
Jan 28, 2026
approval
DAYSEE (ETHINYL ESTRADIOL) — FDA approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
→
Feb 17, 2026
approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (ETHINYL ESTRADIOL) — FDA approval
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
→
Trials studying NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
- phase1A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
- phase1A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
- phase1Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
- phase1A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity
- phase1A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives
- phase1A Study of Elenestinib in Healthy Adult Female Participants
- phase1Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
- phase1Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 1, 2027
284 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (5)
- Mar 11, 2029formulationUS 84153322.6y
- Feb 2, 2029method-of-use (U-1090)US 77049842.5y
- Feb 2, 2029method-of-use (U-1)US 77049842.5y
- Dec 5, 2028method-of-use (U-1)US 78551902.3y
- Jun 1, 2027compositionUS 7838042284d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 28m ago
Found something off?
comments(0)
5-min edit window · permanent after that